Comparison of efficacy and safety between third-dose triple and third-dose dual antihypertensive combination therapies in patients with hypertension

Ki Chul Sung, Soon Jun Hong, Moo Yong Rhee, Myung Ho Jeong, Dae Hee Kim, Sang Wook Lim, Kyungil Park, Jin Bae Lee, Seok Yeon Kim, Jin Man Cho, Goo Yeong Cho, Jung Ho Heo, Sang Hyun Kim, Hae Young Lee, Weon Kim, Deok Kyu Cho, Sungha Park, Jinho Shin, Wook Bum Pyun, Kihwan KwonSeung Woon Rha, Jin A. Jung

Research output: Contribution to journalArticlepeer-review

Abstract

We compared the efficacy and safety of third-standard-dose triple and third-standard-dose dual antihypertensive combination therapies in patients with mild to moderate hypertension. This was a phase II multicenter, randomized, double-blind, parallel-group trial. After a 4-week placebo run-in period, 245 participants were randomized to the third-dose triple combination (ALC group; amlodipine 1.67 mg + losartan potassium 16.67 mg + chlorthalidone 4.17 mg) or third-dose dual combination (AL group; amlodipine 1.67 mg + losartan potassium 16.67 mg, LC group; losartan potassium 16.67 mg + chlorthalidone 4.17 mg, AC group; amlodipine 1.67 mg + chlorthalidone 4.17 mg) therapy groups and followed up for 8 weeks. The mean systolic blood pressure (BP) reduction was -18.3 ± 13.2, -13.0 ± 13.3, -16.3 ± 12.4, and -13.8 ± 13.2 mmHg in the ALC, AL, LC, and AC groups, respectively. The ALC group showed significant systolic BP reduction compared to the AL and AC groups at weeks 4 (P =.010 and P =.018, respectively) and 8 (P =.017 and P =.036, respectively). At week 4, the proportion of systolic BP responders was significantly higher in the ALC group (42.6%) than in the AL (22.0%), LC (23.3%), and AC (27.1%) groups (P =.013, P =.021, and P =.045, respectively). At week 8, the proportion of systolic and diastolic BP responders was significantly higher in the ALC group (59.7%) than in the AL (39.3%) and AC (42.4%) groups (P =.022 and P =.049, respectively) at week 8. Third-standard-dose triple antihypertensive combination therapy demonstrated early effective BP control compared to third-standard-dose dual combination therapies, without increasing adverse drug reactions in patients with mild-to-moderate hypertension.

Original languageEnglish
Pages (from-to)429-439
Number of pages11
JournalJournal of Clinical Hypertension
Volume25
Issue number5
DOIs
StatePublished - May 2023

Bibliographical note

Publisher Copyright:
© 2023 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC.

Keywords

  • combination therapy
  • hypertension
  • low-dose

Fingerprint

Dive into the research topics of 'Comparison of efficacy and safety between third-dose triple and third-dose dual antihypertensive combination therapies in patients with hypertension'. Together they form a unique fingerprint.

Cite this